Stifel Financial Corp Has $15.83 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Stifel Financial Corp lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 17.0% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 142,075 shares of the specialty pharmaceutical company's stock after purchasing an additional 20,675 shares during the quarter. Stifel Financial Corp owned about 0.23% of Jazz Pharmaceuticals worth $15,829,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock worth $46,000 after buying an additional 121 shares in the last quarter. Arizona State Retirement System lifted its holdings in Jazz Pharmaceuticals by 0.8% in the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company's stock worth $1,770,000 after buying an additional 130 shares in the last quarter. Itau Unibanco Holding S.A. boosted its holdings in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after purchasing an additional 172 shares during the last quarter. Finally, Waterfront Wealth Inc. boosted its holdings in Jazz Pharmaceuticals by 2.5% in the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company's stock valued at $1,004,000 after purchasing an additional 230 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Robert W. Baird raised their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a report on Monday, November 18th. Royal Bank of Canada restated an "outperform" rating and issued a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, TD Cowen reduced their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.33.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,753 shares of company stock worth $816,289. Corporate insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded up $0.81 during midday trading on Wednesday, hitting $120.96. The company's stock had a trading volume of 291,835 shares, compared to its average volume of 666,824. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.31 billion, a PE ratio of 16.92, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57. The stock's 50-day moving average price is $116.59 and its 200-day moving average price is $111.85.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.